Workflow
嘉必优: 嘉必优生物技术(武汉)股份有限公司关于本次交易摊薄即期回报情况及采取填补措施的说明公告

Core Viewpoint - The company plans to acquire a 63.2134% stake in Shanghai Ouyi Biomedical Technology Co., Ltd. through a combination of issuing shares and cash payments, while also raising supporting funds to enhance its financial position and operational capabilities [1][2]. Financial Impact of the Transaction - The transaction is expected to significantly impact the company's financial metrics, with total assets projected to increase from 166,459.35 million to 290,530.85 million, a rise of 74.54% [2] - Total liabilities are anticipated to surge from 12,318.99 million to 65,283.53 million, reflecting a staggering increase of 429.94% [2] - Revenue is expected to grow from 38,714.79 million to 65,503.66 million, marking a 69.20% increase [2] - Net profit is projected to rise from 8,116.22 million to 12,068.97 million, indicating a growth of 48.70% [2] Measures to Mitigate Immediate Return Dilution - The company will accelerate the integration of the acquired assets to enhance its ongoing operational capabilities [3] - Governance structures will be optimized to improve operational efficiency and ensure compliance with relevant laws and regulations [3] - The company will enhance its profit distribution policy to strengthen investor return mechanisms, committing to cash distributions when feasible [3] Commitments from Major Stakeholders - The controlling shareholder and actual controller have committed to not interfere with the company's management and to uphold the interests of the company [4] - Board members and senior management have pledged to avoid unfair benefit transfers and to align their compensation with the execution of return mitigation measures [5][7]